Sign in

    IQVIA Holdings Inc (IQV)

    You might also like

    Business Description

    IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, operating through three main segments . The company offers mission-critical information, technology solutions, and real-world insights, primarily serving biopharmaceutical clients with outsourced clinical research and trial services . IQVIA also provides healthcare provider and patient engagement services, contributing to its comprehensive suite of offerings .

    1. Research & Development Solutions (R&DS) - Provides outsourced clinical research and trial services primarily for biopharmaceutical clients, making it the largest contributor to IQVIA's total revenue.
    2. Technology & Analytics Solutions (TAS) - Offers mission-critical information, technology solutions, and real-world insights, significantly contributing to the company's revenue.
    3. Contract Sales & Medical Solutions (CSMS) - Delivers healthcare provider and patient engagement services, enhancing the company's comprehensive service offerings.

    Q2 2024 Summary

    Initial Price$253.33April 1, 2024
    Final Price$208.49July 1, 2024
    Price Change$-44.84
    % Change-17.70%

    What went well

    • IQVIA achieved strong bookings with a book-to-bill ratio of 1.27, representing the third highest bookings ever and is considered very strong by the company.
    • Mission-critical projects that were previously delayed are now proceeding, leading to an expected TAS growth of 6% to 7% in the second half of the year at constant currency.
    • The company is enhancing efficiency and margins through productivity programs, cost containment, and deployment of AI within operations to offset pricing pressures from clients.

    What went wrong

    • Pricing pressure from large pharma clients is increasing due to their multibillion-dollar cost-cutting programs, leading to tougher negotiations and potential margin compression. ,
    • 30% of the TAS business is "essentially flattish", requiring the remaining 70% to grow at high single digits to meet overall targets, highlighting uneven performance across business segments.
    • Despite raising revenue and EPS guidance, EBITDA guidance was slightly lowered due to unfavorable business mix, indicating potential profitability concerns.

    Q&A Summary

    1. EBITDA Guidance and Revenue Mix
      Q: Why lower EBITDA guidance despite higher revenue and EPS?
      A: Management explained that the tweaks in guidance are due to business mix changes affecting margins, but they are still delivering margin growth of about 30 basis points at the midpoint and 50 at the high end. The higher revenue is partly driven by slightly favorable FX.

    2. TAS Performance and Outlook
      Q: What's driving TAS improvement and expectations for second half?
      A: TAS is expected to grow 6% to 7% in the second half. The data business remains flat, but other segments, including real-world evidence, are picking up, with real-world growing in the high single to low teens. Delayed projects are now proceeding, contributing to the improvement.

    3. Pricing Pressure from Clients
      Q: How are pricing pressures affecting the business?
      A: Large pharma clients are implementing cost-cutting programs, leading to tougher price negotiations. Pricing continues to be challenging in both TAS and R&DS, but decision timelines are improving, giving confidence in forecasts.

    4. Bookings and Pipeline Growth
      Q: Are bookings and pipeline improving? Could book-to-bill accelerate?
      A: Bookings are strong with a book-to-bill ratio of 1.27x, the third highest ever. Qualified pipeline is up 12%, and RFP flows are up mid-teens percentage. Management is satisfied with current performance and doesn't anticipate a need for acceleration.

    5. Backlog Burn Rate and Conversion
      Q: What's the outlook for backlog burn rate and revenue conversion?
      A: Backlog burn rate remains around 7% to 7.1%, consistent with previous quarters. Next 12 months' revenue from backlog is $7.8 billion, up 6.9% from $7.3 billion last quarter, indicating confidence in revenue growth.

    6. Clinical Trial Cancellations
      Q: Are clinical trial cancellations improving?
      A: Cancellations have been slightly higher due to large pharma reprioritizing programs in response to the IRA. Average quarterly cancellations are around $500 million, within normal variability.

    7. M&A Activity and Capital Deployment
      Q: Can you discuss M&A contribution and future plans?
      A: Acquisitions have contributed about 1 point to growth this year. While they haven't spent as much as desired due to high valuations, they aim to spend more in the second half. Leverage ratio improved to 3.25x EBITDA, down from the high 4s.

    8. Winning Business from Top Clients
      Q: How did you win business from a top 5 client?
      A: The client preferred IQVIA's solution, which better aligned with their goals. Details of the program were not disclosed.

    9. EBP Funding and Revenue Mix
      Q: How will strong EBP funding affect revenue mix and services?
      A: Strong EBP funding is positive for mid- to long-term prospects but won't immediately change the revenue mix due to long cycles. Increased EBP work will lead to a higher mix of full-service projects over FSP in the future.

    10. Decision-Making Timelines
      Q: Are clients making decisions faster?
      A: Yes, decision-making timelines have improved broadly, not just for mission-critical projects. This contributes to more confident forecasts.

    Key Metrics

    View all financials →

    Executive Team

    NamePositionStart DateShort Bio
    Ari BousbibChairman and Chief Executive OfficerOctober 2016Ari Bousbib has been the Chairman and CEO of IQVIA since October 2016, following the merger of Quintiles and IMS Health. He previously served as Chairman and CEO of IMS Health from 2010 until the merger .
    Ronald E. BruehlmanExecutive Vice President and Chief Financial OfficerAugust 1, 2020Ronald E. Bruehlman is the EVP and CFO at IQVIA. He was appointed to this position effective August 1, 2020. He previously served as SVP and CFO of IMS Health from July 2011 until the merger with Quintiles .
    W. Richard Staub, IIIPresident, Research & Development SolutionsSeptember 25, 2023W. Richard Staub, III resumed his role as President of R&D Solutions on September 25, 2023. He was a senior advisor to the Chairman and CEO from April 2022 to September 2023 and previously held the same position from 2016 to 2022 .
    Kevin C. KnightlyPresident, Corporate Strategy and Enterprise NetworksJuly 2022Kevin C. Knightly has served as President, Corporate Strategy and Enterprise Networks since July 2022. He was previously President, Technology & Commercial Solutions from October 2016 to June 2022 .
    Eric SherbetExecutive Vice President, General Counsel and SecretaryMarch 2018Eric Sherbet has been the EVP, General Counsel, and Secretary of IQVIA since March 2018. Before joining IQVIA, he was the General Counsel and Secretary at Patheon N.V. from 2014 to 2017 .
    Kevin C. KnightlySenior Advisor to the CEOMay 15, 2024 (expected)The documents do not provide information about Kevin C. Knightly serving as Senior Advisor to the CEO effective May 15, 2024. However, he has served as President, Corporate Strategy and Enterprise Networks since July 2022 .

    Questions to Ask Management

    1. Given that TAS revenue growth was approximately 3% in Q1 and 4% in Q2, what gives you confidence that TAS will achieve 6% to 7% growth in the second half, and what are the specific drivers behind this acceleration?
    2. Could you elaborate on the mix shift impacting margins in the second half, and specifically, what intra-segment factors are contributing to the slight lowering of EBITDA guidance?
    3. With large pharma reprioritizing their portfolios and increased cancellations of clinical trials, how is this affecting your R&DS bookings and backlog, and have cancellation trends improved recently?
    4. Considering the recent acceleration in EBP funding, how should we think about the potential shift in revenue mix between EBP and large pharma clients, and what implications does this have for your full-service versus FSP offerings?
    5. Given your strong cash flow performance and reduced leverage to 3.25x EBITDA, what are your priorities for capital allocation, particularly regarding M&A opportunities versus returning capital to shareholders?

    Share Repurchase Program

    Program DetailsProgram 1
    Approval DateOctober 30, 2013
    End Date/DurationNo expiration date
    Total additional amount$11,725 million
    Remaining authorization amount$2,163 million
    DetailsThe program can be modified, extended, suspended, or discontinued at any time.

    Past Guidance

    Q4 2023 Earnings Call

    • Issued Period: Q4 2023
    • Guided Period: FY 2024
    • Guidance:
      • Total Revenue: $15.400 billion to $15.650 billion
      • Adjusted EBITDA: $3.700 billion to $3.800 billion
      • Adjusted Diluted EPS: $10.95 to $11.25
      • Net Interest Expense: Approximately $650 million
      • Operational Depreciation and Amortization Expense: Approximately $580 million
      • Effective Income Tax Rate: Just under 20%
      • Average Diluted Share Count: Approximately 184 million shares
      • Deployment: Assumes about $2 billion deployment split evenly between acquisitions and share repurchase
      • Foreign Currency Rates: Assumes that foreign currency rates as of February 12 continue for the balance of the year
      • Segment-level guidance:
        • TAS Revenue: $6 billion to $6.2 billion
        • R&DS Revenue: $8.7 billion to $8.8 billion
        • CSMS Revenue: Approximately $700 million, which is down slightly year-over-year .

    Q1 2024 Earnings Call

    • Issued Period: Q1 2024
    • Guided Period: Q2 2024 and FY 2024
    • Guidance:
      • Full-Year Revenue: $15.325 billion to $15.575 billion
      • Adjusted EBITDA: $3.7 billion to $3.8 billion
      • Adjusted Diluted EPS: $10.95 to $11.25
      • Second Quarter Revenue: $3.740 billion to $3.815 billion
      • Second Quarter Adjusted EBITDA: $870 million to $890 million
      • Second Quarter Adjusted Diluted EPS: $2.54 to $2.64
      • Foreign Currency Rates: Assumes that foreign currency rates as of April 30, 2024, continue for the balance of the year .

    Q2 2024 Earnings Call

    • Issued Period: Q2 2024
    • Guided Period: Q3 2024 and FY 2024
    • Guidance:
      • Revenue: $15,425 million to $15,525 million for the full year
      • Adjusted EBITDA: $3,705 million to $3,765 million for the full year
      • Adjusted Diluted EPS: $11.10 to $11.30 for the full year
      • Third Quarter Revenue: $3,830 million to $3,880 million
      • Third Quarter Adjusted EBITDA: $925 million to $950 million
      • Third Quarter Adjusted Diluted EPS: $2.76 to $2.86
      • Foreign Currency Rates: Assumes that foreign exchange rates as of July 18, 2024, continue for the balance of the year .

    Q3 2024 Earnings Call

    • Issued Period: Q3 2024
    • Guided Period: N/A
    • Guidance: The documents do not contain information about the Q3 2024 earnings call for IQVIA. Therefore, I cannot provide the guidance metrics from that specific call.

    Competitors

    Competitors mentioned in the company's latest 10K filing.

    • Accenture
    • Aetion
    • Panalgo (a Norstella company)
    • Cognizant Technology Solutions
    • Fortrea
    • Deloitte
    • Pharmaceutical Product Development, Inc. (now part of Thermo Fisher Scientific Inc.)
    • Relx
    • IBM
    • Infosys
    • Cerner (an Oracle company)
    • McKinsey
    • NielsenIQ
    • Optum Insight
    • Parexel International Corporation
    • Press Ganey
    • RTI Health Solutions
    • ICON plc
    • Definitive Healthcare
    • Cegedim
    • Tempus
    • Merative
    • CompuGroup Medical
    • Medidata
    • Clarivate
    • Veeva
    • ZS Associates
    • Syneos Health
    • Amplity Health
    • Eversana
    • Inizio
    • EPS Corporation
    • Uniphar
    • CMIC HOLDINGS Co., Ltd.